Evidence map›Paper›PMID 42523856›Full record

ArticleJournal of diabetes and metabolic disorders2026

Statin Use Patterns among hypertensive Patients in a population-based study.

Alireza Azarboo, Yosef Farzi, Mina Mirzad, Ali Golestani, Sepehr Khosravi, Ozra Tabatabaei-Malazy, Mahnaz Pejman Sani

Abstract read
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alireza Azarboo *Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Yosef Farzi *Department of Industrial Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Mina Mirzad *Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ali GolestaniNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Sepehr KhosraviNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ozra Tabatabaei-Malazy *Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-0188-9721
Mahnaz Pejman Sani *Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although previous studies have assessed the role of statins in managing cardiovascular risk and reducing blood pressure, few have examined their use patterns in relation to hypertension control at population level. This study addresses this gap among Iranian hypertensive patients. Methods: A cross-sectional analysis was conducted using data from the 2021 WHO STEPwise approach to Non-communicable Disease Risk Factor Surveillance (STEPS) in Iran, encompassing all 31 provinces. The study included 6,216 adults aged ≥ 25 years with hypertension, defined as systolic blood pressure (SBP) ≥ 140 mmHg, diastolic blood pressure (DBP) ≥ 90 mmHg, or current use of antihypertensive medication. Participants with missing data for key variables were excluded. Logistic and linear regression models were used to examine associations between statin use, demographic and clinical characteristics, and blood pressure control (SBP < 140 mmHg and DBP < 90 mmHg). Results: Among included 6,216 hypertensive patients, 1,815 (29.2%) were statin users, predominantly older (mean age: 61.79 years) and female (63.14%). Statin use was significantly associated with a 2.04 mmHg reduction in SBP (95% CI: -3.59, -0.48), whereas the association with DBP was non-significant (0.38 mmHg increase in (95% CI: -0.67 to 1.44). In fully adjusted models, statin use was not associated with blood pressure control (OR = 0.98, 95% CI: 0.79-1.21). Conclusion: Despite the high frequency of comorbidities in patients with hypertension, statin use remains low, which needs to great attention by clinicians. In addition, the observed association between statin use and blood pressure in current study is required to further clinical trials or cohort studies to confirm. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-026-02018-y.

Indexed as

Antihypertensive therapyCardiovascular riskDyslipidemiaHypertensionStatins

Identifiers

PMID42523856
PMCPMC13407804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.